Press Releases

pSivida Reports Safety and Efficacy Results from 18-Month Interim Readout of Human PK Iluvien(R) Study WATERTOWN, Mass., Sep 29, 2009 (BUSINESS WIRE) -- pSivida Corp (NASDAQ: PSDV)(ASX: PVA), a leading drug delivery company that has developed two of the only three products approved by the FDA for

pSivida Corp. Reports Results for the Fourth Quarter and Fiscal Year Ended June 30, 2009 WATERTOWN, Mass. --(BUSINESS WIRE)--Sep. 24, 2009-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA) (FF: PV3), a drug delivery company with two of the only three ophthalmic sustained release delivery products approved

pSivida Anounces New Iluvien(R) Pilot Study in Patients with Macular Edema Secondary to Retinal Vein Occlusion WATERTOWN, Mass. --(BUSINESS WIRE)--Sep. 23, 2009-- pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FWB:PV3), a leading drug delivery company that has developed two of the only three products

pSivida CEO to Discuss New Technologies in Retinal Drug Delivery at 5th Annual Ophthalmic Drug Development and Delivery Summit BOSTON --(BUSINESS WIRE)--Sep. 18, 2009-- pSivida Corp , (NASDAQ:PSDV)(ASX:PSD)(FF:PSI), a leading drug delivery company, today announced that Dr.

pSivida Corp Announces Q4 and Fiscal Year 2009 Financial Results Release Date and Conference Call Information WATERTOWN, Mass. --(BUSINESS WIRE)--Sep. 17, 2009-- pSivida Corp. (NASDAQ:PSDV), (ASX:PVA), (FF:PV3), a leading drug delivery company, today announced that its financial results for the

pSivida to Webcast Presentation at Rodman & Renshaw Health Care Conference BOSTON --(BUSINESS WIRE)--Sep. 9, 2009-- pSivida Corp , (NASDAQ:PSDV)(ASX:PSD)(FF:PSI), a leading drug delivery company, today announced it will webcast a live presentation at the Rodman & Renshaw Annual Health Care

Potential Additional Eye Disease Treatment Applications for the Company's Iluvien Product

pSivida Corp. Reports Results for the Quarter ended March 31, 2009 WATERTOWN, MA – May 14, 2009 -- pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FF: PV3), a drug delivery company with the only two ophthalmic sustained delivery products approved by the FDA for treatment of back of the eye diseases, today

Highlights Emerging Technologies and Clinical Data on New and Existing Products

pSivida's Iluvien Phase III Study passes final DSMB Review Watertown, MA. (April 9, 2009) – pSivida Corp. (NASDAQ:PSDV, ASX:PVA, FF:PV3), a leading drug delivery company, today reported that an independent Data Safety Monitoring Board (DSMB) has recommended the continuation of two pivotal Phase III

pSivida CEO to Present at IBC Ocular Angiogenesis Conference Boston, MA (March 30, 2009) – pSivida Corp., (NASDAQ:PSDV, ASX:PSD, FF:PV3), a leading drug delivery company, today announced that Dr. Paul Ashton, President and Chief Executive Officer, will make a presentation on ocular drug delivery

Favorable 12-Month Interim Safety and Efficacy Results from Iluvien Human PK Study Watertown, MA - March 13, 2009 - pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FF:PV3), a leading drug delivery company, today reported the interim 12-month safety and efficacy results from the first human pharmacokinetic

pSivida to Present at Cowen Health Care Conference in Boston BOSTON--(Business Wire)-- pSivida Corp, (NASDAQ:PSDV)(ASX:PSD)(FF:PSI), a leading drug delivery company, today announced it will webcast a live presentation at the Cowen & Company Annual Health Care Conference in Boston, March 16. Dr.

Enrollment complete in BrachySil Dose Ranging Study Watertown, MA – March 5, 2009 – pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FF: PSI), a leading drug delivery company today announced the completion of enrollment of the BrachySil™ (P32 BioSilicon™) dose ranging clinical trial.

Dr. Paul Ashton appointed President and CEO Watertown, MA – February 3, 2009 – pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FF: PSI), a leading drug delivery company today announced that Paul Ashton, Ph.D. has been named President and Chief Executive Officer. Dr. David J.

pSivida New Evaluation for Cardiovascular Drug Delivery Watertown, MA (December 16, 2008) - Drug delivery company pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FF: PV3) has entered into a technology evaluation agreement to evaluate cardiovascular delivery of drugs using pSivida's drug delivery

pSivida new clinical trial for drug delivery device in AMD Watertown, MA (December 12, 2008) – Drug delivery company pSivida Corp (NASDAQ: PSDV, ASX: PVA, FF: PV3) today announced that a clinical trial has begun using its MedidurTM delivery technology to treat a form of dry-Age related Macular

pSivida’s BrachySil pancreatic cancer treatment featured on the BBC Watertown, MA (December 3, 2008) – pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FF: PV3), a drug delivery company, today announced that its lead oncology product, BrachySilTM for the treatment of pancreatic cancer, has been featured in a